Table 2. Summary of studies reporting the use of anticoagulation for portal vein thrombosis in cirrhosis.

*Two patients were excluded

NR: not reported; P: prospective; PVT: portal vein thrombosis; R: retrospective; RCT: randomized control study; LMWH: low-molecular-weight heparin; CS: cross-sectional study

Author/year	Study design	Study population	Anticoagulated patients/controls	Age (years)	Follow-up (months)	Duration of anticoagulation (months)	Type of anticoagulation	PVT recanalization	PVT unchanged	PVT extension	Bleeding outcomes
Wang et al. (2016) [72]	P, RCT	Cirrhotic patients with PVT who underwent TIPS placement	31 treated	54.5	12	12	Warfarin	31/31	0/31	0/31	3 gastrointestinal (1 variceal)
			33 untreated	55				30/32	1/32	1/32	2 gastrointestinal (1 variceal)
Chen et al. (2015) [73]	R, CS	Cirrhotic patients with nonmalignant PVT	30 treated	44.9	33	7.6	Warfarin	15/22	4/22	3/22	4 hematemesis/malena, 1 epistaxis, 3 gingival
			36 untreated	47.8				4/16	6/16	6/16	NR
Chung et al. (2014) [74]	R, CS	Cirrhotic patients with nonmalignant PVT	14 treated	59.4	4	3.7	Warfarin	11/14 (6 complete, 5 partial)	2/14	1/14	NR
			14 untreated	58.7				5/14 (3 complete, 2 partial)	2/14	3/14	1 variceal, 1 subarachnoid hemorrhage
Senzolo et al. (2012) [75]	P, CS	Cirrhotic patients with nonmalignant PVT	35 treated*	55.5	24	6	LMWH	12/33 complete, 9/33 partial (>50%)	7/33	5/33	1 cerebral, 1 epistaxis, 1 hematuria, 1 variceal
			21 untreated	52.3				1/21	NR	15/21	5 variceal